Undisclosed Macrocyle Programs
Oncology
Pre-clinicalActive
Key Facts
About Circle Pharma
Circle Pharma, founded in 2014, is a private biotech company pioneering the development of macrocyclic drugs for oncology. Its core asset is the MXMO™ discovery platform, which aims to systematically design and optimize macrocycles to inhibit challenging intracellular targets. The company is pre-clinical/pre-revenue, building a pipeline focused on transforming cancer treatment through improved selectivity and patient experience. Leadership includes CEO David J. Earp, who brings extensive experience in biotech IP, legal affairs, and corporate development.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |